Every year, adverse drug reactions cause an estimated 2 million hospitalizations and 100,000 deaths in the United States alone. Many of these reactions are not unpredictable — they are the result of prescribing standard doses of medications to patients whose genetic makeup processes those drugs differently.
Pharmacogenomics — the study of how genetic variation affects drug response — is the science of matching the right medication, at the right dose, to the right patient. It is one of the most immediately actionable applications of genomic data.
Why the same drug works differently for different people
Most medications are metabolized by a family of liver enzymes called cytochrome P450 (CYP450). Your DNA determines how active these enzymes are. Depending on your genetic variants, you may metabolize a given drug:
- Normally (extensive metabolizer) — the drug works as expected at standard doses
- Too slowly (poor metabolizer) — the drug accumulates to dangerous levels, causing toxicity or severe side effects
- Too quickly (ultra-rapid metabolizer) — the drug is cleared before it can take effect, leading to treatment failure
- Slightly reduced (intermediate metabolizer) — dose adjustment may be needed
For medications with a narrow therapeutic window — where the difference between an effective dose and a toxic dose is small — these genetic differences can be the difference between healing and harm.
Medications most affected by pharmacogenomics
The FDA has added pharmacogenomic information to the labels of more than 300 medications. Among the most clinically significant:
- Clopidogrel (Plavix): Used to prevent blood clots after heart attacks and stents. Approximately 30% of patients carry CYP2C19 variants that reduce the drug's activation, increasing the risk of cardiovascular events.
- Warfarin: A blood thinner where dosing is heavily influenced by CYP2C9 and VKORC1 variants. Genetic-guided dosing significantly reduces the risk of both under- and over-anticoagulation.
- Codeine: Metabolized by CYP2D6 into morphine. Ultra-rapid metabolizers can convert codeine into dangerously high morphine levels — a particular risk for children. The FDA issued a black-box warning for this interaction.
- Statins (simvastatin): SLCO1B1 variants increase the risk of statin-induced myopathy. Patients with this variant may need an alternative statin or a reduced dose.
- Antidepressants (SSRIs): CYP2D6 and CYP2C19 variants affect the metabolism of commonly prescribed antidepressants including sertraline, fluoxetine, and escitalopram. Dose adjustments based on metabolizer status can improve efficacy and reduce side effects.
- Tamoxifen: Used in breast cancer treatment. CYP2D6 poor metabolizers may not convert tamoxifen into its active form, potentially reducing its effectiveness.
What a pharmacogenomic report contains
A pharmacogenomic report from Dante Labs identifies your metabolizer status across key cytochrome P450 genes and other pharmacogenes. For each gene, the report provides:
- Your diplotype — the combination of variants you carry on both copies of the gene
- Your predicted metabolizer phenotype (poor, intermediate, normal, rapid, ultra-rapid)
- A list of affected medications with guidance on clinical implications
- References to Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines — the gold standard for pharmacogenomic dosing recommendations
The report is designed for physician use. It does not tell you to change your medications — it provides your doctor with the genetic information needed to make more informed prescribing decisions.
Why WGS is better than standalone PGx panels
Standalone pharmacogenomic panels typically test 10–20 genes. This is useful but limited. Whole genome sequencing captures all pharmacogenes simultaneously — including rare variants that may not be included on a standard panel.
More importantly, WGS provides a complete genetic dataset. If a new drug-gene interaction is discovered after your test, your Dante genome data can be re-analyzed to check for the relevant variant — without requiring a new test. Standalone panels can only report on the genes they were designed to test.
A practical example
A 45-year-old patient receives a coronary stent and is prescribed clopidogrel — the standard antiplatelet therapy. Six months later, they suffer another cardiac event. Post-event analysis reveals they are a CYP2C19 poor metabolizer — meaning clopidogrel was never effectively activated in their body. They are switched to prasugrel, an alternative antiplatelet that does not require CYP2C19 activation.
Had the patient's pharmacogenomic profile been known before the initial prescription, the alternative drug could have been prescribed from the start — potentially preventing the second cardiac event entirely.
This is not a hypothetical scenario. It happens daily in cardiology units around the world.
The bottom line
Pharmacogenomics is not futuristic medicine. It is current, evidence-based, and endorsed by major medical organizations. The data is already in your genome — the only question is whether it has been read.